--- title: "SOPHiA GENETICS (NASDAQ:SOPH) Hits New 52-Week High After Analyst Upgrade" type: "News" locale: "en" url: "https://longbridge.com/en/news/294976572.md" description: "SOPHiA GENETICS (NASDAQ:SOPH) reached a new 52-week high following analyst upgrades from BTIG and HC Wainwright, raising price targets to $9.00 and $14.00 respectively. The stock also benefited from raised 2026 revenue guidance, a Q2 revenue beat, and an AstraZeneca partnership. However, the company reported a Q2 loss per share that missed estimates. Additionally, CEO Ross Muken sold shares under a pre-arranged plan." datetime: "2026-08-05T13:40:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294976572.md) - [en](https://longbridge.com/en/news/294976572.md) - [zh-HK](https://longbridge.com/zh-HK/news/294976572.md) --- # SOPHiA GENETICS (NASDAQ:SOPH) Hits New 52-Week High After Analyst Upgrade SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday after BTIG Research raised their price target on the stock from $8.00 to $9.00. BTIG Research currently has a buy rating on the stock. SOPHiA GENETICS traded as high as $7.20 and last traded at $7.0120, with a volume of 2764 shares. The stock had previously closed at $6.84. Get **SOPHiA GENETICS** alerts: A number of other research analysts also recently weighed in on SOPH. HC Wainwright upped their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Wednesday. Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $10.00. **Check Out Our Latest Analysis on SOPHiA GENETICS** ## Insider Activity at SOPHiA GENETICS In other news, CEO Ross Muken sold 9,838 shares of SOPHiA GENETICS stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.22, for a total value of $51,354.36. Following the sale, the chief executive officer owned 670,651 shares in the company, valued at $3,500,798.22. This trade represents a 1.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jurgi Camblong sold 50,069 shares of the business's stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20. Following the sale, the chief executive officer directly owned 3,601,493 shares of the company's stock, valued at $20,888,659.40. This represents a 1.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 221,092 shares of company stock valued at $1,250,070. 4.88% of the stock is currently owned by company insiders. ## Key Headlines Impacting SOPHiA GENETICS Here are the key news stories impacting SOPHiA GENETICS this week: - Positive Sentiment: **Raised 2026 outlook:** SOPHiA GENETICS increased its full-year revenue guidance to $94 million-$96 million, representing 22%-24% year-over-year growth and exceeding the approximately $93.4 million analyst consensus. Management also expects to reach adjusted EBITDA breakeven by year-end, an important milestone for the currently loss-making company. SOPHiA GENETICS 2026 outlook - Positive Sentiment: **Revenue beat and improving EBITDA:** Second-quarter revenue rose 27% year over year to $23.3 million, ahead of the $21.7 million consensus estimate. The adjusted EBITDA loss narrowed 27% to $8.8 million, indicating progress toward profitability. SOPHiA GENETICS Q2 2026 results - Positive Sentiment: **AstraZeneca partnership:** The company entered a multiyear global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision-oncology therapies. The agreement could expand SOPHiA’s role in pharmaceutical development and commercial testing, although financial terms were not disclosed. SOPHiA GENETICS AstraZeneca collaboration - Negative Sentiment: **Bottom-line miss:** SOPHiA GENETICS reported a second-quarter loss of $0.26 per share, worse than the $0.21 consensus estimate. Net loss remained elevated at $22.4 million, while reported and adjusted gross margins declined from the prior-year period. SOPHiA GENETICS earnings report ## Hedge Funds Weigh In On SOPHiA GENETICS A number of hedge funds have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC raised its stake in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Principal Financial Group Inc. raised its stake in SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Archon Capital Management LLC lifted its holdings in SOPHiA GENETICS by 3.4% in the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company's stock valued at $2,061,000 after purchasing an additional 14,342 shares in the last quarter. Finally, Hodges Capital Management Inc. purchased a new position in SOPHiA GENETICS in the 1st quarter valued at $2,157,000. Institutional investors and hedge funds own 31.59% of the company's stock. ## SOPHiA GENETICS Stock Performance The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The firm's 50 day simple moving average is $5.52 and its 200-day simple moving average is $5.11. The company has a market cap of $588.24 million, a price-to-earnings ratio of -13.48 and a beta of 0.96. SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analysts' expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%. On average, sell-side analysts predict that SOPHiA GENETICS SA will post -0.58 EPS for the current year. ## About SOPHiA GENETICS (Get Free Report) SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets. The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders. ## Further Reading - Five stocks we like better than SOPHiA GENETICS - CoreWeave Powers Up: The Asia Infrastructure Grab - Boot Barn Stock Still Has Room to Run, But It Must Earn Its Premium - Palantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started? - Visa’s BioCatch Deal Could Make Fraud Prevention a Bigger Business _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in SOPHiA GENETICS Right Now? Before you consider SOPHiA GENETICS, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list. While SOPHiA GENETICS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [SOPH.US](https://longbridge.com/en/quote/SOPH.US.md) - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [PFG.US](https://longbridge.com/en/quote/PFG.US.md) ## Related News & Research - [SOPHiA GENETICS Updates Investors With Q2 2026 Form 6-K Filing](https://longbridge.com/en/news/294815095.md) - [SOPHiA GENETICS Reports Second Quarter 2026 Results | SOPH Stock News](https://longbridge.com/en/news/294809092.md) - [SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $28,300.00 in Stock](https://longbridge.com/en/news/294114870.md) - [Astrazeneca Plc (NYSE:AZN) Receives Average Recommendation of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/294163603.md) - [Basecamp Wealth Advisors LLC Cuts Stock Holdings in Astrazeneca Plc $AZN](https://longbridge.com/en/news/294653825.md)